long-termextensionofmrz-9605reisbergetal-华译网翻译公司.pdf

翻译样稿(Translation Sample) 北京华译网翻译公司(Beijing HuayiNet Translation Company) Long-term extension of MRZ-9605 (Reisberg et al, 2006)58 Following on from the 28-week, double-blind phase of study MRZ-9605, 175 ‘completers’ (memantine or placebo) were re-titrated and continued on open-label memantine (20 mg/day) for a further 24 weeks. Patients remained blinded to their initial 28-week treatment. In the double-blind phase, patients who took memantine declined at a significantly slower rate than those who took placebo.10 In the long-term analysis, efficacy measures assessed the rate of decline in patients over the whole 52-week period, in the domains of global status, function and cognition. Results • The rate of decline in patients in the former placebo group slowed significantly upon their switch to memantine in the extension phase – the change in rate of decline was statistically significant in all three domains (Figure 6.18). • The rate of decline in patients who received memantine in both phases of the study varied across efficacy measures. Comparing outcome in the open-label phase with the double-blind phase, the rate of global decline decreased significantly (p0.001, OC analysis), the rate of cognitive decline remained unchanged, and the rate of functional decline increased (Figure 6.19). Long-term extension of Lu-99679 (Bakchine et al, 2007)59 The 148-week extension of study Lu-99679 assessed the decline/rate of disease progression of patients treated with memantine compared to untreated patients, and TEAEs between groups. Completers of the 24-week, randomised, double-blind, placebo-controlled, 6-month